12:00 PM EST - Cardiol Therapeutics Inc : Announces the initiation of a Phase II open-label pilot study (NCT05494788), to investigate the tolerance, safety, and efficacy of CardiolRx™ in patients with recurrent pericarditis. In addition to standard safety assessments, the study is designed to evaluate improvement in objective measures of disease, and during an extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids, while taking CardiolRx™. Cardiol Therapeutics Inc
shares T.CRDL are trading up $0.06 at $1.07.
